6533b86dfe1ef96bd12ca17b
RESEARCH PRODUCT
Prevalence of Age-Related Macular Degeneration in Europe
Johanna M. ColijnGabriëlle H.s. BuitendijkElena ProkofyevaDalila AlvesMaria L. CachuloAnthony P. KhawajaAudrey Cougnard-gregoireBénédicte M.j. MerleChristina KorbMaja G. ErkeAlain BronEleftherios AnastasopoulosMagda A. Meester-smoorTatiana SegatoStefano PiermarocchiPaulus T.v.m. De JongJohannes R. VingerlingFotis TopouzisCatherine Creuzot-garcherGeir BertelsenNorbert PfeifferAstrid E. FletcherPaul J. FosterRufino SilvaJean-françois KorobelnikCécile DelcourtCaroline C.w. KlaverSoufiane AjanaBlanca Arango-gonzalezVerena ArndtVaibhav BhatiaShomi S. BhattacharyaMarc BiarnésAnna BorrellSebastian BührenSofia M. CaladoJohanna M. ColijnAudrey Cougnard-gregoireSascha DammeierEiko K. De JongBerta De La CerdaCécile DelcourtAnneke I. Den HollanderFrancisco J. Diaz-corralesSigrid DietherEszter EmriTanja EndermannLucia L. FerraroMíriam GarciaThomas J. HeesterbeekSabina HonischCarel B. HoyngEveline KerstenEllen KilgerCaroline C.w. KlaverHanno LangenImre LengyelPhil LuthertCyrille MaugeaisMagda Meester-smoorBénédicte M.j. MerleJordi MonésEverson NogocekeTunde PetoFrances M. PoolEduardo RodríguezMarius UeffingKarl U. Ulrich Bartz-schmidtElisabeth M. Van LeeuwenTimo VerzijdenMarkus ZumbansenNiyazi AcarEleftherios AnastosopoulosAugusto Azuara-blancoArthur BergenGeir BertelsenChristine BinquetAlan BirdLionel BrétillonAlain BronGabrielle BuitendijkMaria Luz CachuloUsha ChakravarthyMichelle ChanPetrus ChangJohanna ColijnAudrey Cougnard-grégoireCatherine Creuzot-garcherPhilippa CumberlandJosé Cunha-vazVincent DaienGabor DeakCécile DelcourtMarie-noëlle DelyferAnneke Den HollanderMartha DietzelMaja Gran ErkeSascha FauserRobert FingerAstrid FletcherPaul FosterPanayiota FountiArno GöbelTheo GorgelsJakob GrauslundFranz GrusChristopher J HammondCatherine HelmerHans-werner HenseManuel HermannRené HoehnRuth HoggFrank HolzCarel HoyngNomdo JansoniusSarah JanssenAnthony P KhawajaCaroline KlaverJean-françois KorobelnikJulia LamparterMélanie Le GoffSergio LealYara LechanteurTerho LehtimäkiAndrew LoteryIrene LeungMatthias MauschitzBénédicte MerleVerena Meyer Zu WestrupEdoardo MidenaStefania MiottoAlireza MirshahiSadek Mohan-saïdMichael MuellerAlyson MuldrewSandrina NunesKonrad OexleTunde PetoStefano PiermarocchiElena ProkofyevaJugnoo S RahiOlli RaitakariLuisa RibeiroMarie-bénédicte RougierJosé SahelAggeliki SalonikiouClarisa SanchezSteffen Schmitz-valckenbergCédric SchweitzerTatiana SegatoJasmin ShehataRufino SilvaGiuliana SilvestriChristian SimaderEric SouiedHenriet SpringelkampRobyn TappFotis TopouzisVirginie VerhoevenTherese Von HannoStela VujosevicKatie WilliamsChristian WolframJennifer YipJennyfer ZerbibIsabella Zwienersubject
0301 basic medicinemedicine.medical_specialtyVisual acuityOPTICAL COHERENCE TOMOGRAPHYMACULOPATHYgenetic structuresPopulationPrevalenceHEART-DISEASEchoroidal neovascularizationSensory disorders Donders Center for Medical Neuroscience [Radboudumc 12]03 medical and health sciencesRotterdam Study0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterBEAVER DAM EYEEpidemiologygeographic atrophymedicineVISUAL IMPAIRMENT[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationPOPULATIONeducation.field_of_studyBIRTH COHORTbusiness.industryMacular degenerationmedicine.diseaseTRENDSConfidence intervaleye diseases3. Good healthEuropean Prospective Investigation into Cancer and NutritionOphthalmology030104 developmental biologyAge-related Macular DegenerationENDOTHELIAL GROWTH-FACTORBLINDNESS030221 ophthalmology & optometryOptometryAge-related Macular Degeneration choroidal neovascularization geographic atrophysense organsmedicine.symptombusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemographydescription
Manuscript no. 2016-1147 Supplemental material is available at www.aaojournal.org/; International audience; [u]Purpose:[/u] Age-related macular degeneration (AMD) is a frequent, complex disorder in elderly of European ancestry. Risk profiles and treatment options have changed considerably over the years, which may have affected disease prevalence and outcome. We determined the prevalence of early and late AMD in Europe from 1990 to 2013 using the European Eye Epidemiology (E3) consortium, and made projections for the future. [u]Design:[/u] Meta-analysis of prevalence data. [u]Participants:[/u] A total of 42 080 individuals 40 years of age and older participating in 14 population-based cohorts from 10 countries in Europe. [u]Methods:[/u] AMD was diagnosed based on fundus photographs using the Rotterdam Classification. Prevalence of early and late AMD was calculated using random-effects meta-analysis stratified for age, birth cohort, gender, geographic region, and time period of the study. Best-corrected visual acuity (BCVA) was compared between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV). [u]Main Outcome Measures:[/u] Prevalence of early and late AMD, BCVA, and number of AMD cases. [u]Results:[/u] Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1% -5.0%) in those aged 55-59 years to 17.6% (95% CI 13.6%-21.5%) in those aged >= 85 years; for late AMD these figures were 0.1% (95% CI 0.04%-0.3%) and 9.8% (95% CI 6.3%-13.3%), respectively. We observed a decreasing prevalence of late AMD after 2006, which became most prominent after age 70. Prevalences were similar for gender across all age groups except for late AMD in the oldest age category, and a trend was found showing a higher prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer >= 80-year-old subjects with CNV were visually impaired (P = 0.016). Projections of AMD showed an almost doubling of affected persons despite a decreasing prevalence. By 2040, the number of individuals in Europe with early AMD will range between 14.9 and 21.5 million, and for late AMD between 3.9 and 4.8 million. [u]Conclusion:[/u] We observed a decreasing prevalence of AMD and an improvement in visual acuity in CNV occuring over the past 2 decades in Europe. Healthier lifestyles and implementation of anti-vascular endothelial growth factor treatment are the most likely explanations. Nevertheless, the numbers of affected subjects will increase considerably in the next 2 decades. AMD continues to remain a significant public health problem among Europeans.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-12-31 |